GlassScriptPhysician profile
Amy J Burrell
NPI 1053718585
$2,406.47
in general payments reported to CMS, 2019-2025
25 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.16 · 2022: $120 · 2024: $1,061 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.61 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $311.73 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $241.17 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.51 | 2024-2025 | Jardiance, Synjardy, Ofev |
| Merck Sharp & Dohme LLC | $234.45 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $186.16 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $167.12 | 2025 | Veozah |
| Novo Nordisk INC | $147.56 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $145.33 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Viiv Healthcare Company | $119.70 | 2022 | |
| Exact Sciences Corporation | $99.35 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $92.16 | 2021 | |
| Phathom Pharmaceuticals, INC. | $64.84 | 2024-2025 | Voquezna |
| Abbvie INC. | $58.95 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $45.36 | 2024-2025 | |
| Eisai INC. | $33.86 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.67 | 2024 | Trintellix |
| Lundbeck LLC | $27.97 | 2025 | Vyepti |
| Dexcom, INC. | $25.71 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $24.77 | 2025 | Keveyis |
| Corcept Therapeutics | $22.36 | 2024 | Korlym |
| Abbott Laboratories | $20.71 | 2025 | Freestyle Libre 3 |
| Optinose US, INC. | $20.16 | 2024 | |
| Axsome Therapeutics, INC. | $18.84 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $13.93 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.10 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Burrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.